Register for our free email digests:
Jessica Merrill
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
Vertex Trikafta Approved As First Triple Combo For Cystic Fibrosis With $311,503 Price Tag
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.
Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
Teva's Opioid Options Come Into More Focus Ahead Of Third Quarter Financials
Investors may have more clarity on Teva's long-term outlook if the generic drug maker reaches a settlement in a big opioid case before it goes to trial in Ohio next week.
Alexion Buys A Complementary Business With Achillion
J&J's Tremfya Gets Its Blockbuster Wings
The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company to raise guidance for the year.
Pfizer Reaffirms CV Disease Commitment With Deal For Akcea's ANGPTL3 Drug
Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.